Market Closed -
Canadian Securities Exchange
12:37:16 2024-03-28 EDT
|
5-day change
|
1st Jan Change
|
0.01
CAD
|
-.--%
|
|
-.--%
|
-33.33%
|
Fiscal Period: August |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
11.42
|
16.08
|
13.21
|
9.358
|
10.35
|
3.599
|
Enterprise Value (EV)
1 |
9.271
|
14.34
|
13.34
|
9.805
|
10.09
|
4.563
|
P/E ratio
|
-15.7
x
|
-5.83
x
|
-4.14
x
|
6.26
x
|
42.8
x
|
-0.73
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
2,021,328
x
|
1,887,543
x
|
2,129,736
x
|
EV / Revenue
|
-
|
-
|
-
|
2,117,733
x
|
1,840,024
x
|
2,700,356
x
|
EV / EBITDA
|
-13.7
x
|
-5.81
x
|
-5.33
x
|
4.2
x
|
10
x
|
-1.11
x
|
EV / FCF
|
-17.7
x
|
-3.32
x
|
-1.77
x
|
-5.96
x
|
-91
x
|
11.4
x
|
FCF Yield
|
-5.66%
|
-30.1%
|
-56.4%
|
-16.8%
|
-1.1%
|
8.81%
|
Price to Book
|
5.65
x
|
2.11
x
|
1.03
x
|
0.63
x
|
0.66
x
|
0.33
x
|
Nbr of stocks (in thousands)
|
35,689
|
57,424
|
82,575
|
85,075
|
89,970
|
89,970
|
Reference price
2 |
0.3200
|
0.2800
|
0.1600
|
0.1100
|
0.1150
|
0.0400
|
Announcement Date
|
17-12-28
|
18-12-24
|
19-12-30
|
20-12-29
|
21-12-29
|
23-02-22
|
Fiscal Period: August |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
|
-
|
-
|
-
|
4.63
|
5.481
|
1.69
|
EBITDA
1 |
-0.6781
|
-2.467
|
-2.503
|
2.332
|
1.007
|
-4.098
|
EBIT
1 |
-0.6875
|
-2.474
|
-2.88
|
1.614
|
0.3058
|
-4.758
|
Operating Margin
|
-
|
-
|
-
|
34.86%
|
5.58%
|
-281.55%
|
Earnings before Tax (EBT)
1 |
-0.7242
|
-2.501
|
-2.912
|
1.494
|
0.2411
|
-4.951
|
Net income
1 |
-0.7242
|
-2.501
|
-2.912
|
1.494
|
0.2411
|
-4.951
|
Net margin
|
-
|
-
|
-
|
32.27%
|
4.4%
|
-292.98%
|
EPS
2 |
-0.0204
|
-0.0480
|
-0.0387
|
0.0176
|
0.002686
|
-0.0550
|
Free Cash Flow
1 |
-0.5246
|
-4.316
|
-7.52
|
-1.645
|
-0.1108
|
0.4018
|
FCF margin
|
-
|
-
|
-
|
-35.52%
|
-2.02%
|
23.78%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
17-12-28
|
18-12-24
|
19-12-30
|
20-12-29
|
21-12-29
|
23-02-22
|
Fiscal Period: August |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
-
|
-
|
0.13
|
0.45
|
-
|
0.96
|
Net Cash position
1 |
2.15
|
1.74
|
-
|
-
|
0.26
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-0.0526
x
|
0.1914
x
|
-
|
-0.2353
x
|
Free Cash Flow
1 |
-0.52
|
-4.32
|
-7.52
|
-1.64
|
-0.11
|
0.4
|
ROE (net income / shareholders' equity)
|
-52%
|
-49.7%
|
-28.2%
|
10.7%
|
1.57%
|
-37%
|
ROA (Net income/ Total Assets)
|
-28.1%
|
-26%
|
-14.5%
|
6.21%
|
1.13%
|
-19.6%
|
Assets
1 |
2.579
|
9.619
|
20.13
|
24.07
|
21.33
|
25.29
|
Book Value Per Share
2 |
0.0600
|
0.1300
|
0.1600
|
0.1800
|
0.1800
|
0.1200
|
Cash Flow per Share
2 |
0.0500
|
0.0300
|
0
|
0
|
0.0100
|
0
|
Capex
1 |
0.13
|
5.19
|
7.27
|
0.65
|
0.61
|
0.06
|
Capex / Sales
|
-
|
-
|
-
|
14.12%
|
11.07%
|
3.5%
|
Announcement Date
|
17-12-28
|
18-12-24
|
19-12-30
|
20-12-29
|
21-12-29
|
23-02-22
|
|
1st Jan change
|
Capi.
|
---|
| -33.33% | 840K | | +39.33% | 6.11B | | -18.38% | 4.35B | | -9.17% | 3.18B | | +3.98% | 3.15B | | -3.41% | 2.51B | | +48.74% | 1.98B | | -4.82% | 1.74B | | -1.24% | 1.63B | | -8.96% | 1.6B |
Alternative Medicine
|